Pharma BD Deal Intelligence
Merck's $95M upfront bet on cCAM's anti-CEACAM1 antibody CM-24 flopped as a Phase 1 monotherapy with no efficacy signal, and Merck discontinued it and returned the rights to the founders. The asset resurfaced years later at Purple Biotech in a combination regimen showing early Phase 2 signal, but Merck never recouped any value from the deal.
Merck paid ~$95M upfront for a single Phase 1 checkpoint antibody that showed no efficacy signal as monotherapy — Merck discontinued it and handed the rights back to the original founders within a few years, who later revived it (as CM24/Purple Biotech) in combination therapy long after Merck had exited.
Full analysis, sources & comparables →Merck signs a $605M deal to bulk up in cancer immunotherapy, adding a Phase 1 anti-CEACAM1 antibody as it widens its checkpoint pipeline beyond Keytruda.
CEACAM1 emerges as a multi-purpose target for cancer immunotherapy with synergistic activity alongside PD-1/PD-L1 blockade, validating the combination thesis…
Kitov to acquire FameWave and CM-24 after Merck's Phase 1 monotherapy study showed no efficacy signals; Merck discontinued development though no safety risks…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck acquired Israeli immuno-oncology biotech cCAM Biotherapeutics for $95M upfront plus up to $510M in milestones, gaining anti-CEACAM1 antibody CM-24, then in Phase 1 evaluation in advanced solid tumors and hematologic malignancies.
Merck paid ~$95M upfront for a single Phase 1 checkpoint antibody that showed no efficacy signal as monotherapy — Merck discontinued it and handed the rights back to the original founders within a few years, who later revived it (as CM24/Purple Biotech) in combination therapy long after Merck had exited.
Assessment window: 10yr post-close.
Advanced or recurrent solid tumors (melanoma, NSCLC, bladder, gastric, colorectal, ovarian) and hematologic malignancies remain difficult to treat despite the rise of immune checkpoint inhibitors. The first generation of PD-1/PD-L1 therapies leaves the majority of patients without durable benefit, driving search for next-generation checkpoints such as CEACAM1, TIM-3 and LAG-3.
By mid-2015 the immuno-oncology landscape was dominated by anti-PD-1 (Merck's own Keytruda/pembrolizumab and Bristol-Myers Squibb's Opdivo/nivolumab) and anti-CTLA-4 (BMS's Yervoy/ipilimumab). Roche/Genentech's Tecentriq (atezolizumab) and AstraZeneca's Imfinzi (durvalumab) were advancing in late-stage trials. Despite these approvals, only roughly 20-40% of metastatic melanoma patients achieved durable response, fueling a wave of next-generation checkpoint targets including TIM-3, LAG-3, and CEACAM1. cCAM's CM-24 (anti-CEACAM1 mAb) entered Phase 1 in 2014 and was differentiated by its dual relevance to TIM-3 biology — CEACAM1 is the heterophilic ligand required for TIM-3-mediated tolerance. The acquisition gave Merck a distinct mechanism complementary to Keytruda for combination strategies, mirroring competitor moves such as BMS picking up Flexus and Novartis partnering with CoStim. The deal mattered because it locked in a checkpoint complementary to PD-1 at a relatively modest preclinical-stage price, supporting Merck's combination-IO thesis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co., Inc. / cCAM Biotherapeutics Ltd. (this deal) | 2015 | $605M | 17 |
| Merck & Co., Inc. / IOmet Pharma Ltd. | 2016 | $400M | 23 |
| Merck & Co., Inc. / Afferent Pharmaceuticals, Inc. | 2016 | $1.2B | 23 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2015 deals · Merck & Co., Inc. deals · Oncology deals